On this page
Vaccine doses to different groups
People aged 65 and older, people belonging to high-risk groups over 18 years of age and severe immunodeficiency patients aged 12 and older
Four vaccine doses and the late autumn booster doses. Late autumn booster doses are recommended regardless of the number of prior doses or the history of coronavirus infections.
People aged 18–64 and children aged 12–17 belonging to high-risk groups
Three doses of the vaccine. One previous coronavirus infection is equivalent to one dose of the vaccine.
Children aged 12–17
Two doses of the vaccine. A third dose of the vaccine may also be given if it is necessary for special reasons, such as a vaccination certificate.
Children aged 6 months – 11 years who belong to risk groups
Children aged 6 months – 11 years who belong to risk groups may benefit from getting vaccinated. The vaccine can be administered following an individual statement from a treating doctor within specialised medical treatment.
Children belonging to risk groups (aged 6 months – 11 years) are given coronavirus vaccinations by appointment at the Malmi centralised maternity and child health clinic service (Malminraitti 17 A). You can book a vaccination appointment by calling the child health clinic’s telephone service, tel. +358 9 3105 5530 (Mon–Fri 8.00–14.00).
Children aged 6 months – 11 years
In the current situation, extensive coronavirus vaccination of young children is not necessary.
Vaccines that are used
*The Comirnaty Omicron vaccine (30 micrograms/dose)(Link leads to external service) is used for people aged 12 and older. *The Comirnaty Omicron vaccine (10 micrograms/dose)(Link leads to external service) isused for children aged 5 to 11. *The Comirnaty Omicron vaccine (3 micrograms/dose)(Link leads to external service) is used for children aged 6 months to 4 years.
*The Novavax Nuvaxovid vaccine(Link leads to external service) is used for the first and second doses for people aged 12 and older. Nuvaxovid can be given as a booster dose to people over 18 years of age if they have medical reasons against taking the other vaccines or do not want to take other vaccines. In children aged 12 to 17, Nuvaxovid can be used as a booster dose if they are at risk and have medical reasons against taking Comirnaty. In Finland, Nuvaxovid is not recommended for men and boys under 30 years of age. Nuvaxovid can be considered among this group of people on the basis of an individual assessment if there is a medical reason against taking an mRNA vaccine.
*Pages available only in Finnish and Swedish.
N.B! The Nuvaxovid vaccine is currently not available.